Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
High inter-patient variability and high spatial heterogeneity are features of colorectal cancer (CRC). This may influence the molecular characterization of tumor tissue, now mandatory for patients with metastatic CRC who are candidates for treatment with an anti-EGFR mAb, as false-negative results can occur, leading to non optimal therapy. Moreover, temporal molecular heterogeneity during treatment is known to influence the response to therapy and prognosis. We present a literature overview of advances made in characterizing molecular heterogeneity in CRC, underlining that the analysis of liquid biopsy could represent an efficient non-invasive tool to overcome the problem. We believe that understanding CRC heterogeneity is fundamental for a more accurate diagnosis, for selecting the best targets to ensure prolonged antitumor response, and for monitoring minimal residual disease and the onset of resistance to therapy, all essential components of successful personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Heterogeneity, or more specifically, the diverse cell populations within the diseased tissue, is the leading cause of treatment failure for many complex diseases, such as cancers1, Alzheimer’s disease2, stroke3, and coronavirus disease 2019 (COVID-19)4, etc., as well as a major obstacle to successful precision medicine5–7.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“The majority of sporadic CRCs (almost 85%) arise from adenomas according to the model proposed by Fearon and Vogelstein in 1990 [16].”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 2×
“Finally, distinct mutations can also co-exist within the cells of a single metastatic lesion [7].”
BackgroundGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“to classify CRCs into four subtypes [12,22,29].”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 2×
“In Europe the overall survival (OS) rate for mCRC is estimated at 12%, with a median OS of 30 months [3].”
BackgroundClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · cited 1×
“The lack of accurate standard methods to assess ITH is currently limiting our ability to explore its clinical implications [39].”
BackgroundIntra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000 · cited 1×
“In fact, a higher spatial and temporal variability of tumor microenvironment components, such as stromal, inflammatory, and microbial cells, may translate into a higher phenotypic heterogeneity of tumor cells [30].”
Background
Cited by
Bhat, A. A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12295 · Cited by 229
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Khaliq, A. M., Erdogan, C., Kurt, Z., Turgut, S. S., Grunvald, M. W., Rand, T., Khare, S., Borgia, J. A., Hayden, D. M., Pappas, S. G., et al. (2022) · Genome Biology · doi:10.1186/s13059-022-02677-z · Cited by 214
“Approximately one third of patients experience disease relapse following curative-intent surgical resection and chemotherapy [2, 3].”
BackgroundPromising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials
Krasteva, N. A., & Georgieva, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061213 · Cited by 161
“CRC most often starts when cells in a polyp begin growing abnormally [49].”
BackgroundLoupakis, F., Sharma, S., Derouazi, M., Murgioni, S., Biason, P., Rizzato, M. D., Rasola, C., Renner, D., Shchegrova, S., Koyen Malashevich, A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00101 · Cited by 130
“Of note, the design of Natera’s mPCR-NGS assay considers clonal heterogeneity, which is a common characteristic of mCRC.(28,29) By contrast, orthogonal ctDNA detection tests such as ddPCR are designed to detect fewer tumor-specific SNVs at a time, providing less coverage for tumor heterogeneity.”
MethodLiao, C., Yu, Y.-L., Lin, Y., Hsu, Y., Chern, Y., Chiang, J., & You, J. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02253-y · Cited by 130
“Because of the heterogeneous nature of CRC, the treatment strategy and outcomes are diverse, even for tumors with the same stage [2].”
Background
Metadata
- Authors
- Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P.
- Affiliations
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
- Corresponding author
- Ulivi, Paola
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-23
- Volume
- 19
- Issue
- 12
- Pages
- 3733
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6321493
- OpenAlex
- W2901481287
- Cited by
- 262
- References
- 116
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 30 · 2023: 25 · 2022: 84 · 2021: 49 · 2020: 20 · 2019: 9
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, tumor heterogeneity, spatial heterogeneity, interpatient variability, metastatic colorectal cancer, anti-EGFR monoclonal antibody, liquid biopsy, minimal residual disease, treatment resistance, personalized medicine, molecular characterization
- MeSH terms
- Liquid Biopsy, Biological Variation, Individual, Humans, Neoplasm Metastasis, Neoplasm Staging, Biomarkers, Tumor, Colorectal Neoplasms, Genetic Heterogeneity, Molecular Diagnostic Techniques, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? https://app.cochat.ai/papers/10.3390/ijms19123733
- The paper
- Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018). Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19123733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.